(667.3) Metformin down-regulates TGF beta signal transduction and production of PAR2 N-terminus cleaving protease activity in an NR4a1 dependent manner in a PC3 prostate cancer cell line

Poster Board Number: A328

Koichiro Mihara (University of Calgary Cumming School of Medicine), Mahmoud Saifeddine (University of Calgary Cumming School of Medicine), Morley Hollenberg (University of Calgary Cumming School of Medicine, University of Calgary Cumming School of Medicine, Snyder Institute for Chronic Diseases)

Objective:  Our aim is to understand the mechanisms of metformin’s antitumor actions

HYPOTHESIS: Metformin is known to have antitumour effects in cancers like head amp; neck cancer, that may involve its regulation of TGF-β signalling, but the metformin receptor mechanisms for this action are not known. We recently discovered that the action of metformin to preserve hypoglycaemia-impaired endothelial cell function regulated by proteinase-activated receptor-2 (PAR2) requires its interaction with the orphan nuclear receptor, NR4A1 (PubMed ID 34452975). PAR2 also plays a role in regulating prostate cancer PC3 cell function whereby autocrine signaling occurs in PC3 cells which secrete a PAR2-cleaving/activating matrix metalloproteinase, MMP2. We hypothesized that metformin can act in PC3 prostate cancer-derived cells via NR4A1 to change TGF-β signalling and to alter the production of PAR-cleaving proteinases.

Methods:  The ability of TGF-β to upregulate connective tissue growth factor (CTGF) mRNA in PC3 cells was measured for metformin treated cells (lt;/=100 μM) that were transfected with NR4A1, C-terminally tagged with red-fluorescent protein (RFP): either wild-type (WT) or mutant (PPGG) murine NR4A1 that does not interact with metformin. TGF-β upregulated CTGF mRNA in PC3 cells was monitored after metformin treatment for 20 hours.  In similarly transfected WT and mutant PPGG NR4A1-expressing PC3 cells, treated or not with metformin (lt;/=100 μM), the cleavage status of dually tagged transfected N-terminal RFP/C-terminal GFP-PAR2 was monitored: (confocal imaging: yellow = intact receptor; green = cleaved receptor). Concurrently, the abundance of MMP activity of PC3 cell supernatants was measured by a fluorogenic MMP substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (ES002). 

Results: The expected TGF-β upregulated CTGF mRNA in PC3 cells was prevented by metformin treatment, but only for cells transfected with the WT and not the mutant PPGG NR4A1. Metformin acted at concentrations (lt;/=100 μM) far lower than those that affect mitochondrial complex I (gt; mM). We also found that in WT, but not PPGG mutant-transfected PC3 cells, metformin (lt;/=100 μM) down-regulated MMP PAR2-cleaving proteinase activity. 

Conclusions: Our results show that low concentrations of metformin (lt;/=100 μM), in the presence of wild-type but not PPGG mutant NR4A1 which does not enable metformin interactions at the NR4A1 alternative ligand binding site, can both block TGF- β signaling and reduce cell-secreted MMP activity that in turn can drive tissue invasion and metastasis via PAR2 activation. Thus, NR4A1 may play a role in the antitumour actions of metformin.

Ride for Dad Alberta-Prostate Cancer Fight Foundation and Canadian Institutes of Health Research